Commodore Capital LP Reports 4.2% Passive Stake in Tyra Biosciences, Inc.

On May 15, 2026, Commodore Capital LP and associated entities filed a Schedule 13G/A regarding their holdings in Tyra Biosciences, Inc. (TYRA). The filing reveals that as of March 31, 2026, Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz beneficially own an aggregate of 2,475,000 shares of Common Stock. This position represents approximately 4.2% of the company's 59,469,687 outstanding shares. Commodore Capital LP serves as the investment manager for Commodore Capital Master LP, while Atkinson and Kramarz act as managing partners exercising investment discretion. Notably, because the ownership level has fallen to 4.2%, the filers indicated that they now own 5% or less of the class of securities. The filing was submitted as an amendment to a previous statement, reflecting an increase from zero reported in the provided metadata, though the current percentage sits below the standard 5% reporting threshold. The filing confirms the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing company control.